Preferential cancer cell uptake of CLR1501 is shown. Fluorescence confocal microscopy illustrates that the fluorescent CLR1404 analogue, CLR1501, is selectively retained in three additional cancer types at 24 hours post treatment. This image relates to a paper that appeared in the June 11, 2014, issue of Science Translational Medicine, published by AAAS. The paper, by Dr. J.P. Weichert at the University of Wisconsin School of Medicine and Public Health in Madison, Wis., and colleagues was titled, "Alkylphosphocholine Analogs for Broad-Spectrum Cancer Imaging and Therapy."
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact Science for permission.